Funding and expenditure

MMV receives funding and support from government agencies, private foundations, international organizations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of research and development (R&D) projects to develop new, effective and affordable medicines for the treatment and prevention of malaria. They also support specific, targeted access and product management (APM) interventions to help ensure that vulnerable populations in malaria-endemic countries can access new malaria medicines.

Since its foundation in 1999, MMV has invested a total of 852 million United States dollars (USD) to build the world’s largest R&D portfolio of new and innovative antimalarial medicines. In 2017, MMV’s total expenditure was USD 74.5 million (up 9% compared to USD 68.5 million expenditure in 2016), of which R&D expenditure amounted to USD 53.9 million (up 9% compared to USD 49.6 million in 2016).

Our 2017–2021 business plan estimates that a minimum of USD 340 million will be required over the period 2018–2021 to sustain our work. With approximately USD 190 million available at the end of 2017 (USD 53 million cash and USD 137 million committed pledges over the period 2018–2021), the organization is currently tracking a shortfall of approximately USD 150 million up to the end of 2021. MMV has several pending proposals to donors and remains active in its resource mobilization and advocacy activities.

Total donations received/pledged 1999–2021:
USD 1.019 billion as at December 2017


MMV expenditure 2017
Total: USD 74.5 million


MMV income and expenditure to date and scenario 2018–2022

More details are available in the Financial Section of our Annual Report.



Updated June 2016